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Introduction {#sec005}
============

Renal cell carcinoma (RCC) is a common malignant tumor. The estimated number of new cases of RCC in the United States in 2015 was 61560, representing approximately 3.7% of all new cases, and the estimated deaths were 14080, accounting for nearly 2.4% of the total cancer mortality\[[@pone.0166482.ref001]\]. Early-stage RCC patients treated with nephrectomy may have a satisfying five-year survival expectancy\[[@pone.0166482.ref002], [@pone.0166482.ref003]\]. Once metastasis occurs, molecular-targeted therapy and immunotherapy are the only ways to treat RCC due to its poor response to radiotherapy and chemotherapy\[[@pone.0166482.ref004]--[@pone.0166482.ref009]\]. TNM staging is typically used to predict the survival of RCC patients in clinical medicine. Relying on this index, we can propose individualized treatments. However, patients with RCC in the same stage may suffer different outcomes, which urges us to find new and more precise biomarkers to assess the prognosis of RCC.

Aerobic glycolysis is the most prominent characteristic of a cancer cell\[[@pone.0166482.ref010]\]. A large amount of lactate is produced during this process. Lactate dehydrogenase (LDH) is a glycolysis enzyme that catalyzes the conversion of pyruvate into lactate and that could potentially play an important role in tumor metabolism. In recent years, a large number of studies have demonstrated that serum LDH levels are linked to the prognosis of RCC\[[@pone.0166482.ref011]--[@pone.0166482.ref015]\]. LDH could be a cheap and simple prognostic index that could be applied in everyday oncologic clinical practice rather than to stratify patients in clinical trials. However, due to different conditions, parameters and other factors included in the studies, the prognostic value of serum LDH in patients with RCC is still inconsistent. Therefore, we conducted this systematic literature review and meta-analysis to research the relationship between serum LDH levels and the prognosis of RCC.

Materials and Methods {#sec006}
=====================

Search strategy {#sec007}
---------------

PubMed, Embase and Web of Science were searched systematically through June 14, 2016. The terms included in the search strategy were as follows: "lactate dehydrogenase or LDH" (all fields), "kidney cancer or renal cancer or renal carcinoma or renal cell carcinoma" (all fields) and "prognosis or prognostic or survival or outcome" (all fields). To guarantee the validity of the retrieved reference lists, each article was screened by two different researchers (Jie Shen and Zhen Chen).

Selection criteria {#sec008}
------------------

Studies were included in our meta-analysis if the following criteria were met: (1) the patients suffered from RCC only, without other malignant tumors; (2) the serum LDH levels were calculated, and the relationship between serum LDH and RCC was mentioned in the article; (3) the values for the hazard ratio (HR) and its 95% confidence interval (CI), overall survival (OS) or disease-free survival (DFS) were mentioned or could be extrapolated; and (4) the studies were written in English. Studies were excluded based on the following criteria: (1) reviews, letters, comments, case reports and conference abstracts; (2) studies with duplicate data; and (3) missing data for further analysis.

Data extraction {#sec009}
---------------

The data were extracted from the articles by two independent authors (Shen and Chen). Details included author, year of publication, country, patient numbers, age of patients, duration of follow-up care, ethnicity, cut-off value, T stage, Furman grade, treatment method, HR and relative 95% CI. In case survival data could only be found in Kaplan--Meier curves, we had to use software designed by Jayne F Tierney and Matthew R Syde\[[@pone.0166482.ref016]\] to digitize and extract HR values and 95% CIs. Moreover, disputed data were only included after discussion between both authors.

Statistical analysis {#sec010}
--------------------

High and low levels of serum LDH were determined according to the cut-off values provided in the articles. In addition, the pooled HRs and their 95% CIs were estimated to evaluate the effective impact of the serum LDH level on survival. We found an observed HR above 1 to be indicative for a poorer prognosis for RCC patients with high serum LDH level. Heterogeneity of combined HRs was tested by applying a Cochran's Q test and Higgins I-squared statistics. If the *P* value was less than 0.05 and/or *I*^*2*^ was larger than 50%, indicative for a significant heterogeneous distribution, a random-effects model (DerSimonian-Laird method) was used. Otherwise, a fixed-effects model (the Mante-Haenszel method) was implemented. The factors that may have led to the existence of heterogeneity were further analyzed. Publication bias was assessed by using Begg's and Egger's tests. All data analyses were performed with STATA 12.0 (Stata Corporation, College Station, TX, USA). Applying a two-sided test, a *P* value lower than 0.05 was defined as statistically significant.

Results {#sec011}
=======

Search results {#sec012}
--------------

The process of searching and filtering of articles is shown in [Fig 1](#pone.0166482.g001){ref-type="fig"}. Initially, a total of 231 articles were listed. After scanning the titles, abstracts, publication categories and full text of each article, 41 articles were shortlisted. Among these, 12 articles were excluded (five lacked some important data, three used continuous or two cut-offs, and four only reported odds ratios or relative risk). Finally, 29 articles, representing 6629 patients with RCC, were included in this meta-analysis\[[@pone.0166482.ref011]--[@pone.0166482.ref015], [@pone.0166482.ref017]--[@pone.0166482.ref040]\].

![Flow diagram of the study selection process.](pone.0166482.g001){#pone.0166482.g001}

Study characteristics {#sec013}
---------------------

The characteristics of the 29 eligible studies are presented in [Table 1](#pone.0166482.t001){ref-type="table"}. The studies were originally published between 2002 and 2016. The 6629 patients were from Canada, China, Czech, Denmark, Germany, Italy, Japan, Netherlands, Poland, Turkey and the USA. Furthermore, Asian nationals account for 19.4% of the patients (1289 patients) and Caucasian patients account for the remaining 80.6% (5340 patients). In this study, 2287 patients in 12 articles were treated with multiple therapies, while 3465 patients in another 12 articles were treated with targeted therapy only. The remaining 1123 patients received surgery only. Meanwhile, OS was mentioned in 25 articles, and PFS was found in 9 articles.

10.1371/journal.pone.0166482.t001

###### Main characteristics of all studies included in the meta-analysis.

![](pone.0166482.t001){#pone.0166482.t001g}

  Author      Year   Country       Number   Age                Follow-up          Ethnicity   Cut-off value   T stage              Furman                                   Tumor type   Survival analysis   Source of HR   Multivariate analysis   Treatment
  ----------- ------ ------------- -------- ------------------ ------------------ ----------- --------------- -------------------- ---------------------------------------- ------------ ------------------- -------------- ----------------------- ------------------
  Chrom       2016   Poland        266      61(22--85)         46.1(41.2--51)     Caucasian   ULN             45/68/109/8          13/127/71/28                             mRCC         OS                  Report         yes                     targeted therapy
  Song        2016   China         74       51.4(20.1--86.8)   38.3(2.3--53.9)    Asian       1.5ULN          27/35/11/1           NR                                       mRCC         OS                  Report         yes                     MT
  Song        2016   China         155      55.3(17.9--86.8)   36.3(4.3--110.5)   Asian       1.5ULN          48/36/11             NR                                       mRCC         OS/PFS              Report         yes                     targeted therapy
  Matrana     2015   USA           88       65(34--90)         29.3(25.4--33.2)   Caucasian   1.5ULN          19/42                NR                                       mRCC         PFS                 SC             yes                     surgery
  Fukushima   2015   Japan         92       65(37--91)         19(1--142)         Asian       1.5ULN          NR                   NR                                       mRCC         OS                  Report         yes                     MT
  Sasaki      2015   Japan         126      67                 30.8               Asian       250U/L          NR                   NR                                       All stage    OS                  Report         yes                     MT
  Bodnar      2015   Poland        58       60(41--78)         NR                 Caucasian   ULN             NR                   NR                                       mRCC         OS                  Report         yes                     targeted therapy
  Kubackova   2014   Czech         836      59(21--83)         NR                 Caucasian   1.5ULN          NR                   NR                                       All stage    OS/PFS              Report         no                      targeted therapy
  Girgis      2014   Canada        385      NR                 NR                 Caucasian   NR              190/35/49/33/78(x)   31/180/103/22/49(x)                      Non-mRCC     OS                  SC             yes                     surgery
  Malik       2014   USA           70       56.5(44--76)       NR                 Caucasian   1.5ULN          NR                   NR                                       All stage    OS                  Report         yes                     MT
  Poprach     2014   Czech         319      62(45--77)         15                 Caucasian   1.5ULN          NR                   NR                                       mRCC         OS/PFS              Report         no                      MT
  Amato       2014   USA           57       NR                 NR                 Caucasian   1.5ULN          NR                   13/39(1,2--3,4)                          All stage    OS                  Report         yes                     MT
  Cetin       2014   Turkey        59       60 (34--80)        15(2--59)          Caucasian   ULN             NR                   NR                                       mRCC         OS                  Report         no                      MT
  Atkinson    2014   USA           185      Over 18            NR                 Caucasian   927             NR                   NR                                       mRCC         OS/PFS              Report         yes                     targeted therapy
  Nakano      2013   Japan         36       65.7               13(2--48)          Caucasian   200U/L          NR                   NR                                       mRCC         PFS                 Report         yes                     targeted therapy
  Kamba       2013   Japan         144      62.9(19--86)       2--218             Caucasian   1.5ULN          NR                   NR                                       mRCC         PFS                 Report         yes                     MT
  Motzer      2013   USA           1059     60(24--87)         NR                 Caucasian   1.5ULN          NR                   NR                                       mRCC         OS/PFS              Report         yes                     targeted therapy
  Armstrong   2012   USA           404      59.4(23--86)       NR                 Caucasian   ULN             NR                   NR                                       mRCC         OS                  Report         yes                     targeted therapy
  Du          2012   China         286      55.72(28--77)      NR                 Asian       1.5ULN          165/55/52/4          17/134/112/23                            mRCC         OS                  Report         yes                     surgery
  Shinohara   2011   Japan         473      64(32--87)         18                 Asian       1.5ULN          NR                   NR                                       mRCC         OS                  Report         yes                     MT
  Abel        2011   USA           75       60(23--80)         15                 Caucasian   ULN             14/16/34/11          12/20/4/32/7(Ⅱ/Ⅲ/Ⅳ/unknown/high grade)   mRCC         OS                  Report         yes                     targeted therapy
  Zhang       2011   China         83       51(27--75)         27(12--46)         Asian       315IU/L         NR                   NR                                       mRCC         PFS                 Report         yes                     targeted therapy
  Aben        2011   Netherlands   328      67.6±11            NR                 Caucasian   1.5ULN          NR                   14/32/43/13/226 (uknown)                 mRCC         OS                  Report         yes                     MT
  Richey      2011   USA           188      60.8(18.2--83.9)   13.1(1.0--64.4)    Caucasian   ULN             45/28/89/26          NR                                       mRCC         OS                  Report         yes                     targeted therapy
  Jeppesen    2010   Denmark       120      58.3(29--73)       48--72             Caucasian   1.5ULN          NR                   NR                                       mRCC         OS                  Report         yes                     MT
  Donskov     2006   Denmark       120      57(19--74)         57(32--73)         Caucasian   1.5ULN          NR                   NR                                       mRCC         OS                  Report         yes                     targeted therapy
  Peccatori   2005   Italy         70       NR                 10                 Caucasian   300U/L          NR                   NR                                       All stage    OS                  Report         yes                     surgery
  Lehmann     2004   Germany       48       63(35--82)         125.3(33.4--156)   Caucasian   183U/L          44761                NR                                       Non-mRCC     OS                  Report         no                      surgery
  Atzpodien   2002   Germany       425      NR                 20(0--157)         Caucasian   220U/L          NR                   NR                                       mRCC         OS                  Report         yes                     MT

Abbreviation: RCC renal cell carcinoma, mRCC metastatic renal cell carcinoma, Non-mRCC non- metastatic renal cell carcinoma, OS overall survival, PFS progression-free survival, HR hazard ratio, NR not report, MT multiple therapy, SC survival curve, ULN upper limits of normal, x status unknown.

Quality assessment {#sec014}
------------------

We assessed the quality of the 29 eligible studies included in our meta-analysis following the guideline of the Newcastle-Ottawa Scale (NOS)\[[@pone.0166482.ref041]\]. The quality of the studies varied from a score of 5 to 9, with a mean of 6. A higher score suggested the use of better methodologies. Therefore, all 29 studies were included in the subsequent analysis.

Overall survival {#sec015}
----------------

In total, 25 studies, including 6278 RCC patients, provided valid data for OS and are presented in [Fig 2A](#pone.0166482.g002){ref-type="fig"}. We used a random model to pool the HRs because of statistical heterogeneity (*I*^*2*^ = 88.7%, *P* \< 0.001). The pooled data demonstrated that high serum LDH predicts worse OS (HR = 2.13, 95% CI = 1.69--2.69, *P* \< 0.001).

![**A.** Forest plots of studies evaluating hazard ratios of elevated serum LDH level in all renal cell carcinoma (RCC) for overall survival. **B.** Forest plot of the relationship between elevated serum LDH level and overall survival in patients with different tumor types.](pone.0166482.g002){#pone.0166482.g002}

In order to further test for heterogeneity among the studies, we performed this meta-analysis on discrete subgroups, including ethnicity, cut-off value, analysis type and tumor type. High serum LDH was linked to a worse OS for all stages of RCC (HR = 2.41, 95% CI = 1.09--5.33, *P* = 0.03), metastatic RCC (HR = 2.02, 95% CI = 1.57--2.59, *P* \<0.001) and non-metastatic RCC (HR = 3.67, 95% CI = 1.33--10.13, *P* = 0.012), as shown in [Table 2](#pone.0166482.t002){ref-type="table"} and [Fig 2B](#pone.0166482.g002){ref-type="fig"}. Serum LDH also showed a statistically significant connection with poor OS in the remaining subgroups: Asian RCC patients (HR = 2.22, 95% CI = 1.27--3.87, *P* = 0.005), Caucasian RCC patients (HR = 2.06, 95% CI = 1.73--2.44, *P* \<0.001), multivariate analysis (HR = 2.11, 95% CI = 1.63--2.71, *P* \<0.001), univariate analysis (HR = 1.98, 95% CI = 1.52--2.56, *P* \<0.001), 1.5 ULN (HR = 1.96, 95% CI = 1.43--2.68, *P* \<0.001), and others (HR = 2.21, 95%CI = 1.73--2.83, *P* \<0.001).

10.1371/journal.pone.0166482.t002

###### Pooled hazard ratios for OS according to subgroup analyses.

![](pone.0166482.t002){#pone.0166482.t002g}

  Outcome subgroup       No. of patients   No. of studies   HR (95% CI)         *P* value   Model    heterogeneity   
  ---------------------- ----------------- ---------------- ------------------- ----------- -------- --------------- ---------
  **Overall survival**   6278              25               2.13(1.69--2.69)    \<0.001     random   88.7%           \<0.001
  **Ethnicity**                                                                                                      
      Asian              1206              6                2.22(1.27--3.87)    0.005       random   86.4%           \<0.001
      Caucasian          5072              19               2.06(1.73--2.44)    \<0.001     random   54.3%           0.003
  **Cut-off value**                                                                                                  
      1.5ULN             4414              13               1.96(1.43--2.68)    \<0.001     random   87.9%           \<0.001
      Others             1864              12               2.21(1.73--2.83)    \<0.001     random   59.4%           0.004
  **Analysis type**                                                                                                  
      Multivariate       5016              21               2.11(1.63--2.71)    \<0.001     random   89%             \<0.001
      Univariate         1262              4                1.98(1.52--2.56)    \<0.001     fixed    43.3%           0.152
  **Tumor type**                                                                                                     
      All stage          1159              5                2.41(1.09--5.33)    0.03        random   77.8%           0.001
      Metastasis         4686              18               2.02(1.57--2.59)    \<0.001     random   89.3%           \<0.001
      Non-metastasis     433               2                3.67(1.33--10.13)   0.012       random   52.8%           0.146

Abbreviation: OS = overall survival; HR = hazard ratio; CI = confidence interval.

Sensitivity analysis {#sec016}
--------------------

Each study was tested for the impact of a single study on the pooled HRs. One study deviated from the rest and may have influenced the stability of the result. After excluding this study, the pooled HRs and 95% CI for OS were 2.11 and 1.8--2.48, which is a further indication of the strength of our meta-analysis.

Progression-free survival {#sec017}
-------------------------

Next, 9 studies contained a total 2905 RCC patients with valid data for PFS, as showed in [Fig 3A](#pone.0166482.g003){ref-type="fig"}. A fixed-effect model was used in the analysis of PFS due to the absence of statistical heterogeneity (*I*^*2*^ = 40.9%, *P* = 0.095). Additionally, the pooled data demonstrated that high serum LDH predicts worse PFS (HR = 1.74, 95% CI = 1.48--2.04, *P* \< 0.001). A subgroup analysis was conducted simultaneously in order to evaluate the heterogeneity of these studies ([Table 3](#pone.0166482.t003){ref-type="table"} and [Fig 3B](#pone.0166482.g003){ref-type="fig"}). A separate meta-analysis, including 5 studies and 2487 Caucasian patients, had a pooled HR for PFS of 1.87 (95% CI = 1.55--2.25; *P* \< 0.001) with moderate heterogeneity among studies (*I*^*2*^ = 11%, *P* = 0.343). Other subgroups, such as the analysis type and tumor type for PFS, were shown to be statistically linked to serum LDH.

![**A.** Forest plots of studies evaluating hazard ratios of elevated serum LDH level in all renal cell carcinoma (RCC) for progression-free survival. **B.** Forest plot of the relationship between elevated serum LDH level and progression-free survival in patients with different tumor types.](pone.0166482.g003){#pone.0166482.g003}

10.1371/journal.pone.0166482.t003

###### Pooled hazard ratios for PFS according to subgroup analyses.

![](pone.0166482.t003){#pone.0166482.t003g}

  Outcome subgroup                No. of patients   No. of studies   HR (95% CI)        *P* value   Model    heterogeneity   
  ------------------------------- ----------------- ---------------- ------------------ ----------- -------- --------------- -------
  **progression-free survival**   2905              9                1.74(1.48--2.04)   \<0.001     fixed    40.9%           0.095
  **Ethnicity**                                                                                                              
      Asian                       418               4                1.48(0.89--2.48)   0.133       random   57.2%           0.072
      Caucasian                   2487              5                1.87(1.55--2.25)   \<0.001     fixed    11%             0.343
  **Cut-off value**                                                                                                          
      1.5ULN                      2601              6                1.84(1.54--2.19)   \<0.001     fixed    5.7%            0.38
      Others                      304               3                1.4(0.7--2.79)     0.344       random   67.3%           0.047
  **Analysis type**                                                                                                          
      Multivariate                1750              7                1.67(1.36--2.06)   \<0.001     fixed    45.8%           0.086
      Univariate                  1155              2                1.88(1.30--2.73)   0.001       random   52%             0.149
  **Tumor type**                                                                                                             
      All stage                   836               1                1.58(1.13--2.20)   0.007       fixed    \-              \-
      Metastasis                  2069              8                2.02(1.57--2.59)   \<0.001     fixed    46.6%           0.069

Abbreviation: DFS = disease-free survival; HR = hazard ratio; CI = confidence interval.

Publication bias {#sec018}
----------------

We assessed the publication bias of OS and PFS. The publication bias of all studies was evaluated using funnel plots and Egger's and Begg's tests. Funnel plots of OS and PFS are presented in [Fig 4A and 4B](#pone.0166482.g004){ref-type="fig"}, respectively. The figures show an existing publication bias for OS (*P* \<0.01 using Egger's test), while a publication bias for PFS does not exist (*P* = 0.531 using Egger's test).

![Funnel plots for the evaluation of potential publication bias.\
(A) Overall survival for all renal cell carcinoma; (B) Progression-free survival for all renal cell carcinoma.](pone.0166482.g004){#pone.0166482.g004}

Discussion {#sec019}
==========

Aerobic oxidation and glycolysis are two different pathways of glucose metabolism responding to distinct demands of oxygen. In most mammalian cells, glycolysis is inhibited under aerobic conditions and mitochondria oxidize pyruvate producing mainly CO~2~ and H~2~O. This phenomenon is known as the Pasteur effect\[[@pone.0166482.ref042]\]. However, in tumor cells, glycolysis is extremely elevated regardless of oxygen availability, which is called the Warburg effect\[[@pone.0166482.ref010]\]. As a result of high glycolysis, the production of lactate is enhanced, creating an acidic microenvironment in the tissues. Normal cells become necrotic due to the change of the transmembrane H^+^ gradient and the degradation of the extracellular matrix in an acidic microenvironment\[[@pone.0166482.ref043]\]. However, tumor cells can resist acidosis and survive in low pH conditions. Meanwhile, acidosis can inhibit the immune response to tumor antigens, which promotes the proliferation and invasion of tumor cells\[[@pone.0166482.ref044]\].

LDH is an essential substance in the Warburg effect and is available in almost all tissues. It has six different iso-enzymes\[[@pone.0166482.ref045]\]. These iso-enzymes are assembled in a homo- or hetero-tetramer structure by two protein subunits: LDHA and LDHB. Different combinations of LDHA and LDHB characterize five subtypes of LDH (LDH-1 to LDH-5)\[[@pone.0166482.ref045]\]. A third protein subunit, which is named LDHC, forms a testis-specific subtype, known as LDH-6\[[@pone.0166482.ref046]\]. The predominant function of LDH is the catalyzation of the reversible reaction of pyruvate to lactate. NAD^+^ is generated concomitantly alongside this process and is essential for the continuous generation of ATP to keep glycolysis running. Among LDH subtypes, the catalytic efficiency of LDH-5 is the highest\[[@pone.0166482.ref047]\]. When RCC tissue necrosis occurred, high level of intracellular LDH was released into blood, improving the serum LDH concentration\[[@pone.0166482.ref010]\]. Moreover, when distant metastasis occurred, tumor cells can disrupt neighboring organs such as liver, lung, and bones. The injury of those organs can also elevate serum LDH level\[[@pone.0166482.ref047]--[@pone.0166482.ref050]\]. Recently, several studies have proved that reduced LDH expression can inhibit the invasion and metastasis of cancer cells by decreasing their ability to proliferate and their resistance to chemotherapy\[[@pone.0166482.ref051]\]. In conclusion, drugs targeting LDH may represent new approaches for the treatment of RCC.

To our knowledge, this meta-analysis is the most comprehensive research to synthetically analyze the prognostic value of serum LDH in patients with RCC. We conclude that an elevated serum LDH is an objective biomarker for worse OS and PFS in RCC patients. Meanwhile, subgroup analyses demonstrated that elevated serum LDH remained a good biomarker regardless of ethnic background, analysis type and HR diagnostic method.

However, this meta-analysis has some limitations. First, we only considered articles mentioning the HR and the 95% CI, while other articles were excluded because they only reported odds ratios and relative risk for survival. Second, due to different standards for the use of cut-off values in the articles, the validity of serum LDH as an important role to predict the prognosis of RCC patients may have been affected. Moreover, serum LDH could have been influenced by other non-neoplastic conditions, such as muscular dystrophy, anemia, heart failure, hepatitis and lung disease. Most articles contained in this meta-analysis did not investigate those factors. Regardless, serum LDH is an important and meaningful biomarker to assess the prognosis of patients with RCC.

In conclusion, this meta-analysis demonstrated that an elevated serum LDH level was connected to a poor prognosis for patients with RCC. The serum LDH was a convenient and cost-effective prognostic indicator, which could be utilized to divide risk stratification and formulate individualized treatments for patients with RCC. Considering the limitation of the present analysis, the more detailed mechanism why or how LDH activity in RCC tumors could elevate serum LDH level is still unclear. We will need to conduct further multicenter studies to confirm our findings and explore the mechanism deeply.
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